Vice President Of Finance, Strategy, And Business Development
CurrentA $4B Denmark-based medical device company. The $400M Interventional Urology division is headquartered in Mpls.Global Leadership Team Report to Pres of Urology,; dotted line to Coloplast CFO. Lead strategy development, portfolio management, forecasting, investment cases, cost control, M&A, pricing, contracting, balance sheet management, and Board of Directors and Investor Relations presentations.FINANCE LEADERSHIP | BUSINESS GROWTH● Lead a global finance team responsible for FP&A, and accounting functions for sales, marketing, regulatory affairs, and manufacturing teams.● Enabled average annual growth of 8%, in a market growing 4% per year, by adding sales and marketing resources.● Drove profit rate improvement of ~½ percentage point each year.● Implemented a Global Pricing and Customer Contracts team. ● Elevated financial understanding and discipline across the global organization by implementing business reviews, long-term financial plans, and establishing bonuses based on achieving operational KPIs. CORPORATE STRATEGY DEVELOPMENT | BUSINESS DEVELOPMENT | M&A● Manage an 8-member global team responsible for developing and implementing long-term organic and in-organic portfolio strategies and gaining support from the CEO, CFO, and Board of Directors.● Lead business development efforts by understanding the Urology market and identifying and acquiring assets to drive long-term profitable growth.● Established valuation, structure, and acquisition processes for multiple organic and inorganic business cases. ● Developed and presented long-range business plans, gaining approval by the Coloplast Board.● Create external presentations used for annual Coloplast Investor Day presentations to investors and analysts.General Manager, Interim Assignment (Sept 2021-Sept 2023)Interim GM for a Urology expansion into a new business in the U.S. Created a start-up environment to ensure Year 1 and Year 2 business objectives were met.